within Pharmacolibrary.Drugs.ATC.C;

model C09DB07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.006166666666666667,
    adminDuration  = 600,
    adminMass      = 0.016,
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Candesartan and amlodipine is a fixed-dose combination of an angiotensin II receptor blocker (candesartan) and a dihydropyridine calcium channel blocker (amlodipine). It is used for the treatment of hypertension, especially in patients where monotherapy is insufficient. Both agents are approved and widely used antihypertensive medications.</p><h4>Pharmacokinetics</h4><p>Estimated PK parameters for oral fixed-dose combination in adults, based on data from individual drugs; no direct literature available for the exact combination product.</p><h4>References</h4><ol><li><p>Kim, JR, et al., &amp; Ko, JW (2018). No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects. <i>Drug design, development and therapy</i> 12 2475–2483. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S172568&quot;>10.2147/DDDT.S172568</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30127595/&quot;>https://pubmed.ncbi.nlm.nih.gov/30127595</a></p></li><li><p>Pandey, AK, et al., &amp; Malhotra, S (2020). Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. <i>Journal of hypertension</i> 38(8) 1593–1602. DOI:<a href=&quot;https://doi.org/10.1097/HJH.0000000000002429&quot;>10.1097/HJH.0000000000002429</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32371763/&quot;>https://pubmed.ncbi.nlm.nih.gov/32371763</a></p></li><li><p>Ferri, N, &amp; Corsini, A (2025). [Clinical pharmacology of combination therapies for the prevention and treatment of cardiovascular diseases]. <i>Giornale italiano di cardiologia (2006)</i> 26(1 Suppl 2) e6–e16. DOI:<a href=&quot;https://doi.org/10.1714/4425.44225&quot;>10.1714/4425.44225</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39898749/&quot;>https://pubmed.ncbi.nlm.nih.gov/39898749</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09DB07;
